FAP and neoplasm: Considering these findings, when designing recombinant proteins targeting the 4-1BB axis, we should consider whether the protein will solely localize to the tumor tissue or if it will also be available to amplify T-cell responses in the tumor-draining lymph nodes, as demonstrated by the FAP–4-1BBL developed by Claus et al94.